Today, Ultragenyx announced Interim data from the Phase 2 portion of the Orbit study, which showed that treatment with setrusumab reduced incidence of fractures in patients with OI by 67% following at least 6 months of treatment and demonstrated improvements in lumbar spine bone mineral density (BMD).
To learn more about Ultragenyx research, visit https://www.ultraclinicaltrials.com/OI or reach out via email, OIStudyInfo@ultragenyx.com.
